Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete … – GlobeNewswire (press release)
|
Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete …
GlobeNewswire (press release) Neuralstem Announces Publication of Data From First-In-Human Study of Human Neural Stem Cell Transplantation for Chronic Spinal Cord Injury -. – First cohort of four subjects with thoracic (T2-T12) ASIA-A grade spinal cord injury in the Phase I study … |
Drug Target Review |
CRISPR approach could limit toxicity of CAR-T therapy in AML
Drug Target Review A new approach may provide a new path towards treating acute myeloid leukaemia (AML) with CAR-T cells. To treat AML, investigators have to target a specific protein – CD33 – that’s also expressed on healthy cells, meaning the therapy cannot attack the … |
